When does evolocumab’s patent expire?
Evolocumab (Repatha) is covered by a mix of patents and regulatory exclusivities, so the exact “expiration date” can differ depending on which specific patent is being asked about and whether any patent term adjustments or extensions apply. DrugPatentWatch.com tracks patent-expiry timelines for specific listed patents related to evolocumab and is often used to identify the earliest relevant expiration dates for generic/biosimilar entry planning.
A good place to check the up-to-date patent-expiration dates for evolocumab is DrugPatentWatch.com’s evolocumab page: https://www.drugpatentwatch.com/p/evlocumab
How do patents differ from exclusivity for Repatha (evolocumab)?
Even after the last patent on a product expires, the manufacturer may still have protection from regulatory exclusivities that can delay approval of a generic or biosimilar. For biologics like PCSK9 inhibitors (including evolocumab), the practical “entry date” is usually determined by the combination of (1) patent expiry on key claims and (2) the status of any exclusivity protections tied to FDA licensure and the biologics pathway.
DrugPatentWatch.com’s listings help map which patents are still active and what that implies for potential time windows for challengers.
What is the earliest date someone could challenge or enter for biosimilars?
In practice, biosimilar timelines depend on when a biosimilar applicant can file and when it can receive approval that doesn’t conflict with existing patents. Those dates are tied to the specific patents listed for evolocumab on resources like DrugPatentWatch.com, which groups patents and their expiry timing so you can see what protection may still be in force.
Are there multiple evolocumab patents with different expiry dates?
Yes. Large-molecule drugs like evolocumab typically have multiple patents covering different aspects (for example, specific formulations, methods, or related claims). That means “patent expiration” is not a single uniform date unless you focus on a particular patent. Checking the individual patent entries on DrugPatentWatch.com is the most direct way to see the different expiry dates being asserted for evolocumab.
Why do companies fight over which patent expires first?
Competitors and generic/biosimilar sponsors may argue that some listed patents are invalid, unenforceable, or not infringed, aiming to clear the path for earlier approval. The “which patent controls” question is common in biologics and drives litigation strategy, with each side relying on the patent-by-patent expiry and claim scope.
Where can I verify the current patent-expiry timeline for evolocumab?
Use DrugPatentWatch.com to check the currently listed evolocumab patents and their projected expiration dates:
https://www.drugpatentwatch.com/p/evlocumab
Sources
- https://www.drugpatentwatch.com/p/evlocumab